StockUS listing USACHFFOTCQBHealthcareEarnings Deterioration

Arch Biopartners Inc(ACHFF) Stock Analysis | Healthcare

USD --+0.00%
Reward32Low
Risk80High
75%Data
Revenue down 61% YoY
USD —+0.00 (+0.00%) Previous close · OTCQB
Market cap 21.87M
Reward Ratingⓘ32 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ80 High risk assessment · 75% data coverage
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ACHFF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Arch Biopartners Inc?

, together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada.

AI Brief Pro

The brief on Arch Biopartners Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Arch Biopartners Inc?

, together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 21.87M.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Elevated volatility implies higher downside and expectation risk.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (32)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta2.046
Insider Activity
12M windowNo data
No insider activity data available for this ticker.